CN1555807A - 一种稳定性提高的灯盏花素注射剂及其制备方法 - Google Patents
一种稳定性提高的灯盏花素注射剂及其制备方法 Download PDFInfo
- Publication number
- CN1555807A CN1555807A CNA2004100138450A CN200410013845A CN1555807A CN 1555807 A CN1555807 A CN 1555807A CN A2004100138450 A CNA2004100138450 A CN A2004100138450A CN 200410013845 A CN200410013845 A CN 200410013845A CN 1555807 A CN1555807 A CN 1555807A
- Authority
- CN
- China
- Prior art keywords
- acid
- breviscapine
- injection
- sodium
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002347 injection Methods 0.000 title claims abstract description 63
- 239000007924 injection Substances 0.000 title claims abstract description 63
- 238000002360 preparation method Methods 0.000 title claims description 28
- 241001013934 Erigeron breviscapus Species 0.000 title description 3
- DJSISFGPUUYILV-UHFFFAOYSA-N UNPD161792 Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-UHFFFAOYSA-N 0.000 claims abstract description 108
- DJSISFGPUUYILV-ZFORQUDYSA-N scutellarin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-ZFORQUDYSA-N 0.000 claims abstract description 106
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000008215 water for injection Substances 0.000 claims abstract description 26
- 150000007524 organic acids Chemical class 0.000 claims abstract description 18
- 239000000843 powder Substances 0.000 claims abstract description 13
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 9
- 239000007951 isotonicity adjuster Substances 0.000 claims abstract description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 42
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 36
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 32
- 150000007530 organic bases Chemical class 0.000 claims description 26
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 20
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 20
- 235000010323 ascorbic acid Nutrition 0.000 claims description 18
- 239000011668 ascorbic acid Substances 0.000 claims description 18
- 229960005070 ascorbic acid Drugs 0.000 claims description 18
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 16
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 16
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 16
- 229960003194 meglumine Drugs 0.000 claims description 16
- 235000010265 sodium sulphite Nutrition 0.000 claims description 16
- 239000011975 tartaric acid Substances 0.000 claims description 16
- 235000002906 tartaric acid Nutrition 0.000 claims description 16
- 235000015165 citric acid Nutrition 0.000 claims description 14
- GQTHJBOWLPZUOI-FJXQXJEOSA-M sodium D-pantothenate Chemical compound [Na+].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GQTHJBOWLPZUOI-FJXQXJEOSA-M 0.000 claims description 14
- 229940068459 sodium pantothenate Drugs 0.000 claims description 14
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 13
- -1 nicotiamide Chemical compound 0.000 claims description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 12
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 12
- 239000003963 antioxidant agent Substances 0.000 claims description 12
- 230000003078 antioxidant effect Effects 0.000 claims description 12
- 235000006708 antioxidants Nutrition 0.000 claims description 12
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 12
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 11
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 10
- 230000001954 sterilising effect Effects 0.000 claims description 10
- 238000004659 sterilization and disinfection Methods 0.000 claims description 10
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 10
- NPLTVGMLNDMOQE-UHFFFAOYSA-N carthamidin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=C(O)C(O)=C2C(=O)C1 NPLTVGMLNDMOQE-UHFFFAOYSA-N 0.000 claims description 9
- 239000008103 glucose Substances 0.000 claims description 9
- 229930190376 scutellarin Natural products 0.000 claims description 9
- 239000004201 L-cysteine Substances 0.000 claims description 8
- 235000013878 L-cysteine Nutrition 0.000 claims description 8
- 239000001384 succinic acid Substances 0.000 claims description 7
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 6
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 6
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 6
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 6
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 6
- 239000001530 fumaric acid Substances 0.000 claims description 6
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 6
- 239000011976 maleic acid Substances 0.000 claims description 6
- 239000001630 malic acid Substances 0.000 claims description 6
- 235000011090 malic acid Nutrition 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 5
- 239000008176 lyophilized powder Substances 0.000 claims description 5
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 5
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 5
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004202 carbamide Substances 0.000 claims description 4
- 239000013522 chelant Substances 0.000 claims description 4
- 229940001468 citrate Drugs 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 235000011087 fumaric acid Nutrition 0.000 claims description 4
- 210000004907 gland Anatomy 0.000 claims description 4
- 229910021645 metal ion Inorganic materials 0.000 claims description 4
- 235000006408 oxalic acid Nutrition 0.000 claims description 4
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 150000002829 nitrogen Chemical class 0.000 claims description 3
- 239000001509 sodium citrate Substances 0.000 claims description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 3
- 239000001508 potassium citrate Substances 0.000 claims description 2
- 229960002635 potassium citrate Drugs 0.000 claims description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 2
- 235000011082 potassium citrates Nutrition 0.000 claims description 2
- 229960001790 sodium citrate Drugs 0.000 claims description 2
- 235000011083 sodium citrates Nutrition 0.000 claims description 2
- 239000003513 alkali Substances 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 abstract description 2
- 230000003064 anti-oxidating effect Effects 0.000 abstract 1
- 230000010412 perfusion Effects 0.000 abstract 1
- 229940090044 injection Drugs 0.000 description 45
- 239000003814 drug Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 150000007529 inorganic bases Chemical class 0.000 description 6
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 239000003978 infusion fluid Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229960004011 methenamine Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- OQUFOZNPBIIJTN-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;sodium Chemical compound [Na].OC(=O)CC(O)(C(O)=O)CC(O)=O OQUFOZNPBIIJTN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410013845 CN1245987C (zh) | 2004-01-08 | 2004-01-08 | 一种稳定性提高的灯盏花素注射剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410013845 CN1245987C (zh) | 2004-01-08 | 2004-01-08 | 一种稳定性提高的灯盏花素注射剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1555807A true CN1555807A (zh) | 2004-12-22 |
CN1245987C CN1245987C (zh) | 2006-03-22 |
Family
ID=34351120
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410013845 Expired - Fee Related CN1245987C (zh) | 2004-01-08 | 2004-01-08 | 一种稳定性提高的灯盏花素注射剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1245987C (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100396289C (zh) * | 2006-05-19 | 2008-06-25 | 昆明龙津药业有限公司 | 灯盏花乙素注射制剂及其制备方法 |
CN100406021C (zh) * | 2006-05-26 | 2008-07-30 | 昆明龙津药业有限公司 | 灯盏花乙素注射制剂及其制备方法 |
CN1965848B (zh) * | 2005-11-14 | 2010-04-21 | 王锦 | 一种灯盏花素冻干粉针剂及其制备工艺 |
CN101336886B (zh) * | 2008-07-02 | 2010-06-09 | 中国药科大学 | 一种灯盏花素的可溶制剂 |
CN1830451B (zh) * | 2005-03-08 | 2010-09-08 | 万生联合制药有限公司 | 灯盏花素葡萄糖注射液的制备方法 |
CN101993462A (zh) * | 2009-08-11 | 2011-03-30 | 昆明制药集团股份有限公司 | 一种灯盏花乙素结晶i及其制备方法 |
CN1839866B (zh) * | 2005-08-13 | 2011-04-20 | 杭州民生药业有限公司 | 一种含有灯盏花素的药物组合物 |
CN102247329A (zh) * | 2010-05-19 | 2011-11-23 | 昆明制药集团股份有限公司 | 5,6,7,4′-四羟基黄酮粉针剂及其制备方法 |
CN102344475A (zh) * | 2010-07-30 | 2012-02-08 | 昆明制药集团股份有限公司 | 一种灯盏花乙素衍生物及其制备方法和应用 |
WO2012028056A1 (zh) * | 2010-09-02 | 2012-03-08 | 昆明制药集团股份有限公司 | 一种灯盏花乙素临床制剂及其制备方法 |
-
2004
- 2004-01-08 CN CN 200410013845 patent/CN1245987C/zh not_active Expired - Fee Related
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1830451B (zh) * | 2005-03-08 | 2010-09-08 | 万生联合制药有限公司 | 灯盏花素葡萄糖注射液的制备方法 |
CN1839866B (zh) * | 2005-08-13 | 2011-04-20 | 杭州民生药业有限公司 | 一种含有灯盏花素的药物组合物 |
CN1965848B (zh) * | 2005-11-14 | 2010-04-21 | 王锦 | 一种灯盏花素冻干粉针剂及其制备工艺 |
CN100396289C (zh) * | 2006-05-19 | 2008-06-25 | 昆明龙津药业有限公司 | 灯盏花乙素注射制剂及其制备方法 |
CN100406021C (zh) * | 2006-05-26 | 2008-07-30 | 昆明龙津药业有限公司 | 灯盏花乙素注射制剂及其制备方法 |
CN101336886B (zh) * | 2008-07-02 | 2010-06-09 | 中国药科大学 | 一种灯盏花素的可溶制剂 |
CN101993462A (zh) * | 2009-08-11 | 2011-03-30 | 昆明制药集团股份有限公司 | 一种灯盏花乙素结晶i及其制备方法 |
CN102247329A (zh) * | 2010-05-19 | 2011-11-23 | 昆明制药集团股份有限公司 | 5,6,7,4′-四羟基黄酮粉针剂及其制备方法 |
CN102247329B (zh) * | 2010-05-19 | 2014-02-05 | 昆明制药集团股份有限公司 | 5,6,7,4′-四羟基黄酮粉针剂及其制备方法 |
CN102344475A (zh) * | 2010-07-30 | 2012-02-08 | 昆明制药集团股份有限公司 | 一种灯盏花乙素衍生物及其制备方法和应用 |
WO2012028056A1 (zh) * | 2010-09-02 | 2012-03-08 | 昆明制药集团股份有限公司 | 一种灯盏花乙素临床制剂及其制备方法 |
CN102379886A (zh) * | 2010-09-02 | 2012-03-21 | 昆明制药集团股份有限公司 | 一种灯盏花乙素临床制剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1245987C (zh) | 2006-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1245987C (zh) | 一种稳定性提高的灯盏花素注射剂及其制备方法 | |
CN109984998B (zh) | 注射用奥美拉唑钠的制备方法 | |
CN1231223C (zh) | 灯盏花素输液制剂及其制备方法 | |
CN1931190A (zh) | 蟾皮提取物、其药物制剂及其制备方法 | |
CN1543976A (zh) | 黄芪甲苷注射剂制剂及其制备方法 | |
CN1526404A (zh) | 抗肿瘤的人参皂苷c-k注射剂及其制备方法 | |
CN1864666A (zh) | 甲磺酸左氧氟沙星冻干粉针注射剂及其制备方法 | |
CN101450051B (zh) | 单体丹酚酸b注射剂及其制备方法 | |
CN1640409A (zh) | 一种高纯度的灯盏花乙素注射剂 | |
CN1919206A (zh) | 牡荆素注射剂及口服制剂 | |
CN1186094C (zh) | 具有促思维记忆功能的吡拉西坦药物组合物及其制备方法 | |
CN1730014A (zh) | 苦木注射剂新的给药途径及其制备工艺、新的适应症 | |
CN1965878A (zh) | 含乙酰谷酰胺和红花有效成分的药物组合物及其制剂 | |
CN1850097A (zh) | 灯盏花乙素注射制剂及其制备方法 | |
CN1733013A (zh) | 毛冬青注射剂新的给药途径及其制备工艺 | |
CN1552425A (zh) | 一种金银花提取物及其制剂与用途 | |
CN1270702C (zh) | 辅酶q10静脉输液及其制备方法 | |
CN1526407A (zh) | 抗肿瘤的原人参二醇注射剂及其制备方法 | |
CN1565446A (zh) | 注射用氟康唑冻干制剂及制备方法 | |
CN1615871A (zh) | 加替沙星静脉输注制剂及其制备方法 | |
CN101507723B (zh) | 一种治疗肺炎和上呼吸道感染的组合药物及其制备方法 | |
CN1172676C (zh) | 一种甘草酸二铵大输液制剂 | |
CN1903190A (zh) | 注射用呋塞米及其制备方法 | |
CN1593591A (zh) | 一种水飞蓟提取物环糊精包合物的制备方法及其药物制剂 | |
CN1526405A (zh) | 抗肿瘤的人参皂苷Rg3注射剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ZHENG FEIXIONG Free format text: FORMER OWNER: CHINA PHARMACY UNIVERSITY Effective date: 20080704 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20080704 Address after: Room 15, block 506, Lake District, Gulou District, Fujian, Fuzhou Patentee after: Zheng Feixiong Address before: Tong Xiang Nanjing city of Jiangsu Province, No. 24 Patentee before: China Pharmaceutical University |
|
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Shanxi Hengda Pharmaceutical Co., Ltd. Assignor: Zheng Feixiong Contract fulfillment period: 2008.11.7 to 2010.3.31 contract change Contract record no.: 2009990000042 Denomination of invention: Stability enhanced erigeron breviscapus injection and its preparation method Granted publication date: 20060322 License type: General permission Record date: 2009.1.19 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: COMMON LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.11.7 TO 2010.3.31; CHANGE OF CONTRACT Name of requester: SHANXI HENGDA PHARMACEUTICAL CO., LTD. Effective date: 20090119 |
|
ASS | Succession or assignment of patent right |
Owner name: FUZHOU KERRY PHARMACEUTICAL CONSULTING CO., LTD. Free format text: FORMER OWNER: ZHENG FEIXIONG Effective date: 20091016 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20091016 Address after: North Bank of the 136 union cup Hotel, drum tower area, Gulou District, Fujian, Fuzhou Province, five Patentee after: Fuzhou Kerry Medical Consulting Co., Ltd. Address before: Room 15, block 506, Lake District, Gulou District, Fujian, Fuzhou Patentee before: Zheng Feixiong |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060322 Termination date: 20160108 |